StockData

Marker Therapeutics vs Xenetic Biosciences

MRKR and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MRKR and XBIO compare

Marker Therapeutics is the larger company, worth 3.7 times as much as Xenetic Biosciences ($13.9M against $3.8M).

Xenetic Biosciences scores higher on the StockData Score (12 against 6 for Marker Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMRKRXBIO
Size and price
Market cap$13.9M$3.8M
Share price$0.837$1.61
Change, 1 year−9.4%−38.1%
Change, 5 years−93.2%−88.9%
Beta (5Y)1.921.14
Employees52
StockData Score
Total score612 (better)
Valuation score13 (better)
Growth score02 (better)
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S–1.2×
P/B1.1×0.6× (better)
Fair value–$4.53
Margin of safety–64.4%
Growth
Revenue growth (TTM)–33.3%
Revenue growth, 5Y average48.0% (better)46.8%
Profitability
Operating margin–−81.0%
Net margin–−75.9%
Return on equity−76.9%−47.0% (better)
Financial health
Debt / equity0.000.00
Current ratio6.037.43 (better)
Altman Z-score−42.52−37.70 (better)
Piotroski F-score25 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions23.8%6.5%
Held by insiders31.9%12.2%
Short interest, % of float1.6%1.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.